Presentation at Next Generation Vaccine Conference

    RNS Number : 3579Z
  Northwest Biotherapeutics Inc
  18 July 2008
   

 For Immediate Release  18 July 2008


    Northwest Biotherapeutics 
    To present at 
    Next Generation Vaccine Conference

    Highlights Include Clinical Trial Updates 

    BETHESDA, MD - July 17, 2008 - Northwest Biotherapeutics, Inc. (OTCBB: NWBO.OB; AIM, NWBTS and NWBT), (the "Company or NWBT"), today
announced that Dr. Alton L. Boynton, its President and Chief Executive Officer, will deliver a presentation updating the Company's progress
in the development of dendritic vaccines for the treatment of cancer, at the "Next Generation Vaccines" conference.  The conference will be
held on 17 &18 July, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, USA. Dr. Boynton is scheduled to
present as part of the Advances in Cancer Vaccines session on July 18th @ 11:15 am EST. 

    Dr. Boynton will provide an update on NWBT's product candidates, including therapeutic cancer vaccines DCVax®-Brain for the treatment of
Glioblastoma multiforme and DCVax®-Prostate for hormone-independent prostate cancer.

    *     Ends -


    For further information, please contact:

 Northwest Biotherapeutics
 Anthony P. Deasey, Chief Financial Officer                [phone]

 Buchanan Communications
 Lisa Baderoon ([e-mail]) / Mary-Jane         [phone]
 Johnson / Catherine Breen 

 Collins Stewart
 Adam Cowen/Tim Mickley                                    [phone]

      
    Notes to Editors
    About Northwest Biotherapeutics
    
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than
current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based
vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and
powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer,
and clearance from the FDA for Phase I trials in five other cancers. The Company has started a Phase I/II trial with DCVax® directed to
ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

    For further information, please visit the company web site at www.nwbio.com

    Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify
forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there
are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability
to raise additional capital, risks related to the Company's ability to enroll patients in the Phase II trial of DCVax®-Brain and complete
the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax®-Brain, risks
related to manufacturing, risks related to the Company's ability to initiate, and enroll patients in, the planned Phase III trial of
DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate or DCVax®-Brain will demonstrate safety and efficacy, and the
timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is
included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the
Company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not
place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a
result of new information, future events or developments, except as required by securities laws.




This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCILFIADIIDLIT